FATE THERAPEUTICS INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
FATE THERAPEUTICS INC (FATE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $5.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- FATE THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $5.89M, a 31.24% decline from fiscal 2024.
- FATE THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $8.56M, a 33.13% decline from fiscal 2023.
- FATE THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $12.80M, a 281.44% increase from fiscal 2022.
- FATE THERAPEUTICS INC effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $3.36M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $5.89M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $8.56M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $12.80M 10-K · filed 2025-03-05 | |
| 2022-12-31 | $3.36M 10-K · filed 2024-02-26 | |
| 2021-12-31 | -$35.85M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $6.07M 10-K · filed 2023-02-28 | -$6.07M 10-K · filed 2021-02-24 |
| 2019-12-31 | $359.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | -$307.00K 10-K · filed 2021-02-24 | |
| 2017-12-31 | $539.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $968.00K 10-K · filed 2019-03-05 | |
| 2015-12-31 | $213.00K 10-K · filed 2018-03-05 | |
| 2014-12-31 | $426.00K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $161.00K 10-K · filed 2016-03-03 | |
| 2012-12-31 | $36.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |